HEALTHWSOC ABC CHARLOTTE
Experimental weight-loss drug moves closer to FDA review
Eli Lilly's experimental weight-loss drug, retatrutide, showed participants lost an average of 50 pounds over 18 months in late-stage trials. The medication targets three hormones related to appetite and metabolism and is under FDA review, with a decision possible by 2027. Common side effects included stomach-related issues.
Mentioned
Related Signal
Adjacent reporting
- STAT+: Lilly’s ‘triple-G’ drug leads to bariatric-surgery levels of weight loss in trial
- New Weight Loss Drug Retatrutide Delivers Stunning Results
- New obesity drug from Lilly delivers major weight loss
- New weight-loss shot appears to outperform other obesity drugs on market
- Eli Lilly says next-generation weight loss drug clears crucial obesity trial
- Eli Lilly says its next gen obesity drug is more powerful than Zepbound and Wegovy